Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals Inc (ACAD), Idera (IDRA) and Pacira Pharmaceuticals (PCRX)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals Inc (ACAD), Idera (IDRA) and Pacira Pharmaceuticals (PCRX) with bullish sentiments.

ACADIA Pharmaceuticals Inc (ACAD)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on ACADIA Pharmaceuticals Inc today and set a price target of $60. The company’s shares closed yesterday at $25.50.

Fein observed:

“Our $60 PT is based on an equally weighted composite of: (a) $71.86/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $3.50 discounted back to and (b) an NPV of $47.36/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.2% and a 44.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals Inc with a $39.67 average price target, a 55.6% upside from current levels. In a report issued on April 25, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

Idera (IDRA)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Idera today and set a price target of $14. The company’s shares closed yesterday at $3.06, close to its 52-week low of $2.25.

Ramakanth commented:

“We maintain our Buy rating of IDRA and our 12-month price target of $14.00 per share. We derive our price target based on a risk- adjusted net present value analysis of projected tilsotolimod revenues through 2027 assuming a 12% discount rate and a 3% terminal growth rate.”

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.3% and a 32.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idera with a $10.50 average price target.

Pacira Pharmaceuticals (PCRX)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $60. The company’s shares closed yesterday at $47.93.

Livnat noted:

“We are adding in Iovera revenue now, and since we’d already put in incremental Opex for the deal upon the announcement, this is all accretive to our estimates now. There remains a lot of ambiguity around Pacira’s Iovera plans, given no color around the manufacturing and clinical strategy, so we’re adding a modest franchise to our model going forward, with admittedly arbitrary growth estimates at this juncture until we get more color. We believe Iovera is a clearly synergistic asset, but until we learn more about reimbursement improvements and/or cash-market uptake, and progress around any potential osteoarthritis plans (which we see as the real blue sky opportunity) we have to be very conservative. Thus, we currently model the franchise revenue only climbing to $24M by 2024, and look forward to more updates there.”

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 10.9% and a 54.9% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $50.38, implying a 5.1% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $57 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts